Previous 10 | Next 10 |
2023-11-15 13:44:49 ET Summary Arcellx's CART-ddBCMA reported strong and competitive data in late-line multiple myeloma patients, positioning it well against CAR-T leader Carvykti. The updated data at ASH show that the efficacy held up and even slightly improved compared to the pr...
2023-11-15 08:24:52 ET Graphite Bio GRPH -15% following reverse merger with LENZ Therapeutics in all-stock deal . Global E Online GLBE -15% on Q3 earnings release . Tivic Health Systems TIVC -15% on Q3 earnings release . reAlpha Tech ( AIRE ) -14%...
2023-11-15 08:15:28 ET Gilead Sciences, Inc. (GILD) Jefferies London Healthcare Conference November 15, 2023, 04:00 AM ET Company Participants Andrew Dickinson - Chief Financial Officer Conference Call Participants Michael Yee - Biotech Analyst, Jeffries ...
2023-11-15 08:10:00 ET Summary S&P 500 and Dow Jones dropped for the third straight month in October, just before staging a remarkable reversal in November. Interest rates were kept steady again in a range of 5.25% to 5.5%, and it is uncertain if 2023 will see yet another hike...
2023-11-15 06:39:59 ET More on Arcellx Arcellx: Clinical Hold Lifted, Charting A Brighter Path Forward (Rating Upgrade) Arcellx jumps after data for Gilead-partnered multiple myeloma drug Seeking Alpha’s Quant Rating on Arcellx Historical earnings data...
ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP PR Newswire -- Arcellx to receive $200M equity investment at $61.68 per share and an $85 million upfront cash payment -- -- Kite exercises option to Arcellx's ARC-SparX program ACLX-001 in multiple myel...
-- The companies expand the scope of their existing collaboration for CART-ddBCMA to include lymphomas -- -- Kite exercises option to Arcellx’s ARC-SparX program ACLX-001 in multiple myeloma -- -- Arcellx to receive $200M equity investment at $61.68 per share and an $85 mil...
2023-11-13 04:53:00 ET Summary Gilead Sciences has seen mixed signals in its earnings and sales growth, but the stock is appealing at lower levels. Gilead's success with a cure for HCV led to a decline in patient population and margin pressure. The company has made acquisition...
2023-11-11 10:00:00 ET Summary October was a challenging month for U.S. equity markets, but there is optimism heading into yearend. The Morningstar Wide Moat Focus Index trailed the S&P 500 in October, but remains ahead year-to-date. Moat stocks have historically rebounded...
2023-11-10 16:05:35 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’...
– New 5-Year Clinical and Real-World Data Reinforce Biktarvy ® as a Long-Term Treatment Option for a Diverse Range of People with HIV, Including Those with Comorbidities – – Investigational, Once-Daily, Once-Weekly and Twice-Yearly Dosing Frequenc...
– PURPOSE 1 Data Showed Zero Infections and 100% Efficacy and Superiority of Lenacapavir to Background HIV Incidence and Daily Truvada ® for PrEP – – If Approved, Lenacapavir Would be the First and Only Twice-Yearly PrEP Choice and Could Address C...